Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
ID: 322177Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/322177

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-20-043.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for Cancer Center Support Grants (CCSGs) aimed at enhancing cancer research within NCI-designated Cancer Centers. This funding opportunity, specifically the P30 Clinical Trial Optional grants, is designed to support both Comprehensive Cancer Centers and Cancer Centers that integrate various research disciplines, fostering a collaborative environment to advance understanding and treatment of cancer. The CCSGs are crucial for establishing a robust research infrastructure that promotes innovative cancer research initiatives across the United States, with applications subject to peer review and a maximum budget limit for new and renewal requests. Interested applicants can find more information and guidelines at the NIH website, and the application deadline is set for October 12, 2121.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-20-043.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications for Cancer Center Support Grants (CCSGs) aimed at promoting cancer research within NCI-designated Cancer Centers. This funding opportunity (PAR-20-043), particularly the P30 Clinical Trial Optional grants, supports comprehensive, clinical, and basic cancer centers to foster a collaborative research environment that integrates various scientific disciplines. The initiative encourages applications from institutions with significant annual NIH cancer-focused funding and promotes innovative interactions, community engagement, and education within the realm of cancer research. The program not only aims to enhance the understanding of cancer but also to improve prevention, diagnosis, and therapeutic strategies, reflecting the NCI’s commitment to advancing cancer science and public health. Applications must comply with specified guidelines and are subject to peer review, with a maximum budget limit established for new and renewal applications. The CCSGs are foundational for research infrastructure, enabling extensive cancer-focused initiatives across the United States.
    Similar Opportunities
    Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for Cancer Center Support Grants (CCSGs) aimed at supporting NCI-designated Cancer Centers through the P30 funding mechanism. This initiative seeks to enhance collaborative cancer research across various domains, including basic laboratory, clinical, and prevention research, with eligibility extending to Comprehensive Cancer Centers, Clinical Cancer Centers, and Basic Cancer Centers that demonstrate significant research capabilities and community engagement. The funding, which has an award ceiling of $1.5 million, is intended to foster transdisciplinary research collaboration, create shared resources, and ensure equitable participation in cancer research across diverse populations. Interested applicants must submit their proposals by January 7, 2026, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at enhancing cancer research through innovative technologies. This initiative encourages currently funded NCI P30 Cancer Center Support Grants (CCSG) recipients to expand their research by integrating new technical approaches developed through the NCI's Innovative Molecular Analysis Technologies (IMAT) program. The program is designed to foster interdisciplinary collaboration and promote independent validation of emerging technologies, thereby accelerating scientific discovery in cancer research. Interested applicants can apply for up to $150,000 per year, with a total funding pool of approximately $600,000 available for up to three awards. Applications are due by 5 PM local time on October 2, 2024, and further inquiries can be directed to grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-015.html.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers through Funding Opportunity Number RFA-DK-25-015. The CCS will collaborate with four PKD Research Core Centers to enhance understanding of PKD and promote resource sharing, providing essential administrative support, managing data sharing, and administering pilot project funding. This initiative is crucial for fostering a diverse and collaborative research environment to address the challenges of PKD effectively. The funding opportunity anticipates approximately $1.1 million for one award in FY 2025, with annual budgets around $350,000. Interested applicants must submit their proposals via Grants.gov by November 14, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    The Chronic Pancreatitis Clinical Research Consortium (CPCRC)- Clinical Centers (CPCRC-CCs) (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Chronic Pancreatitis Clinical Research Consortium (CPCRC), inviting U01 applications for Clinical Centers to conduct research on chronic pancreatitis, diabetes, and pancreatic cancer. The initiative aims to continue the consortium's work by collecting clinical data and biospecimens to identify biomarkers for risk stratification and disease progression, ultimately enhancing understanding and treatment of these conditions. With an estimated funding of $6.5 million for the 2025 fiscal year, applications are due by October 18, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention Clinical Trials Network (CP-CTNet) to establish sites for early-phase cancer prevention clinical trials. The initiative aims to develop and conduct trials that assess the safety and efficacy of various preventive agents and interventions targeting specific biological processes associated with cancer development, with a focus on recruiting high-risk participants and conducting multi-institutional studies. This funding underscores the importance of advanced research in cancer prevention, with a total funding amount of $8.75 million annually to support five awards over six years, each with a budget not exceeding $1.375 million. Interested applicants must submit a letter of intent by August 23, 2024, and a complete application by September 30, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Outstanding Investigator Award (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NCI Outstanding Investigator Award (R35), aimed at providing long-term support for exceptional cancer research projects. This grant opportunity is designed for accomplished investigators with a proven track record in cancer research, allowing them to pursue innovative and high-risk projects that could lead to significant advancements in the field. The award offers up to $600,000 in direct costs per year for a maximum duration of seven years, with applications due by November 7, 2024. Interested applicants can find more information and contact details at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html.